Jeffrey A. Bluestone, PhD elected to Gilead Sciences Board of Directors
Gilead Sciences has appointed Jeffrey A. Bluestone to its Board of Directors. Jeffrey is currently President and Chief Executive Officer of Sonoma Biotherapeutics. He is also the A.W. and Mary Margaret Clausen Distinguished Professor in the Diabetes Center at University of California San Francisco. He was previously President and Chief Executive Officer of the Parker Institute for Cancer Immunotherapy, and guided the National Cancer Moonshot Initiative as a Member of the Blue Ribbon Panel.
Gilead Sciences, Inc. is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. Headquartered in Foster City, CA, the company currently employs approximately 12,000 people. Gilead generated $22.45 billion in revenue for fiscal year 2019.